Supplementary Figure S1 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies

Di Kang; Yanping Wang; Yiwei Lin; Wen Wee; Daniel Morgensztern; Konstantinos Leventakos; Chao Bi; Yuli Ding; Jing Xiong; Man Yan; Xin Sun; Peng Wang; Cunbo Ma; Yinxiang Wang

doi:10.1158/1078-0432.29568221

July 15, 2025

Supplementary Figure S1 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies

View at Publisher

Ask AI

Bookmark

Share

Key Points

The main finding reveals that RMC-4550 acts as a potent allosteric shp2 inhibitor in cancer treatment.
Key evidence shows enhanced efficacy of combined therapies using RMC-4550 alongside RTK/RAS/MAPK and PD-1 blockade.
The approach involved synthesizing RMC-4550 and analyzing its chemical structure through NMR and HPLC techniques.
This research advances cancer treatment options by targeting shp2, potentially improving patient outcomes with combination therapies.

Implication

The allosteric shp2 inhibitor RMC-4550 improves treatment outcomes in rtk, ras, and mapk pathways, suggesting its potential in cancer therapy.

Abstract

Supplementary Figure S1. RMC-4550 was synthesized in house. A. The chemical structure of RMC-4550. B. NMR spectrum of RMC-4550. C. HPLC spectrum of RMC-4550.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kang et al. (2025) studied this question.

synapsesocial.com/papers/689a02bce6551bb0af8cc6e3 https://doi.org/10.1158/1078-0432.29568221

View at Publisher

Ask AI

Bookmark

Share

Supplementary Figure S1 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies

Key Points

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure S1 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

Keep reading

More related papers